The studies tested the parp inhibitors niraparib zejula, olaparib. The clinical trials on this list are studying olaparib. Olaparib has shown significant clinical benefit as maintenance therapy in women with newly. Genentechroche demonstrated a statistically significant and clinically meaningful improvement in progressionfree survival pfs in women with newlydiagnosed advanced ovarian cancer. Olaparib for metastatic breast cancer in patients with a germline brca mutation. Pdf olaparib for the treatment of ovarian cancer researchgate. The initial approval of olaparib in december 2014 by the fda was as monotherapy in patients with deleterious or suspected deleterious germline brcam as detected by an fdaapproved test advanced ovarian cancer. Olaparib parp inhibitor is a new drugoral tablets medicated at the dose of 400mg bdused in the treatment of ovarian cancer patients with present brca mutations in two settings, namely, as maintenance therapy after standard chemotherapy based on paclitaxel and carboplatin has been completed, given after recurrence of platinumsensitive ovarian cancer, or as the third and.
Olaparib displays benefit in clinical trials of brca mutationharboring ovarian and breast cancers as well as prostate, pancreatic, and nonsmall cell lung cancers nsclc. Ovarian cancer is the seventh most common cancer in women worldwide and is the leading cause of death from gynecologic cancers in highincome countries. Treatment is continued until disease progression or unacceptable. Capsules are taken orally twice a day, treatment is supplied every 28 days one cycle.
The case for the combination of olaparib lynparza and durvalumab imfinzi in patients with metastatic breast cancer and relapsed ovarian cancer with germlinebrcamutations was strengthened based on. Niraparib is a poly adenosine diphosphate ribose polymerase inhibitor which uses the concept of synthetic lethality in the presence of a mutation in the breast cancer susceptibility gene brca. Study evaluating the efficacy of maintenance olaparib and. Pdf polyadpribose polymerase inhibitors parpis are the most active and interesting therapies approved for the treatment of epithelial ovarian. Clinical trials look at new ways to prevent, detect, or treat disease. In 2014, fda approved olaparib capsules for the treatment of advanced ovarian cancer in patients with inherited brca mutations who have received three or more types of chemotherapy.
Clinical trials are research studies that involve people. Olaparib is used to treat some types of ovarian, fallopian tube or primary peritoneal cancer that have come back after other treatments. Most women with newly diagnosed advanced ovarian cancer have a relapse within. Bc cancer protocol summary for maintenance treatment of. Olaparib in the management of ovarian cancer ovarian symptom index fosi and the trial outcome index t oi have been used to me asure healthre lated qol.
American cancer society, american society for colposcopy and cervical pathology, and american society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. Nct01078662 demonstrated an objective response rate orr of 46% in a small number of patients with platinumsensitive ovarian cancer who. Ovarian cancer is the leading cause of death from gynecologic tumors in the western world. Efficacy and safety of olaparib maintenance therapy in. Patient counseling and management of symptoms during olaparib therapy for recurrent ovarian cancer. Olaparib as maintenance treatment for patients with. Ovarian cancer, fallopian tube cancer, peritoneal cancer, breast cancer, pancreatic cancer lynparza olaparib.
Olaparib, a potent oral poly adpribose polymerase inhibitor, exhibits antitumor activity and prevents the recurrence in advanced ovarian cancer. Olaparib tablets for maintenance treatment in ovarian cancer. Dnarepair defects and olaparib in metastatic prostate cancer. Olaparib for the treatment of platinumsensitive relapsed ovarian cancer olaparib lynparza capsule formulation received approval based on the results from study 19. Apr 16, 2019 four trials reported the data concerning os in ovarian cancer with 353 patients in olaparib groups compared to 214 patients in other intervention groups. As such, parp inhibitors have the potential to be beneficial in a much wider proportion of ovarian cancer patients than was originally proposed. You have chemotherapy before you start taking olaparib. The recommended dose of olaparib is 300 mg two 150 mg tablets taken orally twice daily with or without food. Fda approves olaparib tablets for maintenance treatment in.
Olaparib lynparza olaparib is also called by its brand name lynparza. It is for people who have a change in a gene called brca. Olaparib for the treatment of platinumsensitive relapsed ovarian cancer olaparib. Olaparib is the only agent available in relapsed ovarian cancer that targets those with brca12 mutations olaparib dose is 400 mg eight 50 mg capsules by mouth twice daily for a total. Lynparza olaparib phase iii solo2 data demonstrated progressionfree survival benefit in brcamutated ovarian cancer as maintenance therapy published 14 march 2017. Olaparib is approved as maintenance therapy in patients with brca mutated platinum sensitive ps recurrent ovarian cancer oc after response to last platinum based therapy. Olaparib azd2281 is a smallmolecule, potent oral parp inhibitor. The use of maintenance therapy with olaparib provided a substantial benefit with regard to progressionfree survival among women with newly diagnosed advanced ovarian cancer and a brca12 mutation. Olaparib is also called by its brand name lynparza. Fda approves olaparib for germline brcamutated metastatic. Parp inhibitors and quality of life in ovarian cancer.
Request pdf olaparib plus bevacizumab as firstline maintenance in ovarian cancer background. Clinical trials using olaparib national cancer institute. This approval was based on study 42 which demonstrated an objective response rate of 30% with olaparib. Although the majority of such patients have no evidence of disease. In a study of two doses of olaparib in brcamutant patients with advanced ovarian cancer, both doses were well tolerated and demonstrated modest effect. Standard therapy for patients with newly diagnosed advanced ovarian cancer consists of cytoreductive surgery and platinumbased chemotherapy. Lynparza is a poly adpribose polymerase parp inhibitor indicated. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline brca12 mutation. On august 17, 2017, olaparib lynparza in tablet form was granted regular approval for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinumbased chemotherapy.
For the management of abnormal cervical screening tests and cancer precursors. It acts against cancers in people with hereditary brca1 or brca2 mutations, which include some ovarian. Olaparib is the most studied parp inhibitor to date in ovarian cancer. Laboratory tests show that it may help slow the growth of ovarian cancer. Olaparib lynparza cancer information cancer research uk. Nct01078662 demonstrated an objective response rate orr of 46% in a small number of patients with platinumsensitive ovarian cancer. In this article, we assessed the efficacy and safety of olaparib maintenance therapy on platinumsensitive ovarian cancer. Olaparib is a parp inhibitor that has been approved for maintenance for brcamutated ovarian cancer in the recurrent and frontline setting as well as for treatment of brcamutated ovarian cancer in patients who have received multiple prior lines of chemotherapy.
Preclinically, this orally active parp inhibitor induces synthetic lethality in cells deficient in brca. Olaparib name of proposed course of treatment include brief explanation if medical term not clear olaparib for the treatment of ovarian cancer. Olaparib maintenance therapy in platinumsensitive relapsed. Lynparza olaparib phase iii solo2 data demonstrated.
A subgroup analysis of data from a phase ii trial of olaparib monotherapy in patients with a gbrcam study 42. Maintenance olaparib in advanced ovarian cancer twice daily or. The studies tested the parp inhibitors niraparib zejula, olaparib lynparza, and veliparib. Ncis basic information about clinical trials explains the types and phases of trials and how they are carried out. Women with newly diagnosed advanced ovarian cancer may benefit from initial treatment with one of several parp inhibitors, according to results from three separate clinical trials. Parp inhibitors as initial treatment for ovarian cancer. Olaparib, sold under the brand name lynparza, is a medication for the maintenance treatment of brcamutated advanced ovarian cancer in adults. Its given if your cancer has come back relapsed after previously having a type of chemotherapy called platinum chemotherapy. Olaparib versus nonplatinum chemotherapy in patients with. In animal models with ovarian cancer xenografts, olaparib. Treatment of gbrcam her2negative metastatic breast cancer.
Olaparib in patients with recurrent highgrade serous or. Fda approved olaparib capsules in 2014 for the treatment of patients with deleterious or suspected deleterious germline brcamutated advanced ovarian cancer who have been treated with three or. Ovarian cancer for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic. Solo1 the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Ovarian cancer is the second the most common gynaecological malignancy in developed countries. Advanced gbrcamutated ovarian cancer treated with 3 or more 17 patient counseling information prior lines of chemotherapy 14. Lynparza approved in eu for the treatment of germline brca. The case for the combination of olaparib and durvalumab in patients with metastatic breast cancer and relapsed ovarian cancer with germline brca mutations was strengthened based on the updated results from the phase iii mediola, which was covered in 2 separate presentations at the 2019 esmo congress. Olaparib maintenance therapy in patients with platinum.
Olaparib is a parp inhibitor that has been approved for maintenance for brcamutated ovarian cancer in the recurrent and frontline setting as well as for treatment of brcamutated ovarian cancer in. Olaparib tablets as maintenance therapy in patients with platinumsensitive, relapsed ovarian cancer and a brca12 mutation solo2engotov21. The first one, approved december 19 th, 2014, was olaparib. Fda expands approval of olaparib for ovarian cancer. Ovarian cancer oc is the leading cause of death in women with gynecological cancer. Olaparib parp inhibitor is a new drugoral tablets medicated at the dose of 400mg bdused in the treatment of ovarian cancer patients with present brca mutations in two settings, namely, as maintenance therapy after standard chemotherapy based on paclitaxel and carboplatin has been completed, given after recurrence of platinumsensitive ovarian cancer. People with ovarian cancer would welcome wider availability of olaparib with a more convenient administration schedule 3.
Pdq supportive and palliative care editorial board. Large genomic rearrangements in the familial breast and ovarian cancer gene brca1 are associated with an increased frequency of high risk features. Ovarian cancer for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum based chemotherapy. Stewart bpharm last updated on jan 1, 2020 fda approved.
Lynparza, innolaparib european medicines agency europa eu. Olaparib as maintenance treatment for patients with platinum. In december 2014, olaparib was the first parp inhibitor to receive us and european regulatory approval in ovarian cancer. A study of olaparib prior to surgery and chemotherapy in. Olaparib maintenance monotherapy in patients with brca. Most patients are diagnosed at advanced stage with poor prognosis.
It acts against cancers in people with hereditary brca1 or brca2 mutations, which include some ovarian, breast, and prostate cancers. The nccn guidelines panel for cervical cancer screening endorses the following guidelines for the prevention and early detection of cervical cancer. Polyadpribose polymerase parp inhibitors were first reported to specifically kill brca1 or brca2deficient cancer cells in 2005, which is an example of synthetic lethality. Maintenance olaparib in patients with newly diagnosed. Olaparib in patients with metastatic castrationresistant. Lynparza olaparib treatment for advanced ovarian cancer. May 22, 2019 the national comprehensive cancer network nccn clinical practice guidelines for ovarian cancer recommend olaparib or niraparib maintenance therapy after partial or complete response to platinum chemotherapy, irrespective of brcam testing. Olaparib, a poly adpribose polymerase parp inhibitor, capitalizes on this concept and is the first drug in its class approved for patients with ovarian cancer. Role of olaparib as maintenance treatment for ovarian. Pdf parp inhibitors in ovarian cancer researchgate. Olaparib lynparza national drug monograph january 2016. Durvalumab treatment in combination with chemotherapy and. Olaparib plus bevacizumab as firstline maintenance in. Icon 9 will assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance olaparib alone following a response to platinumbased chemotherapy in women with relapsed platinumsensitive ovarian, fallopian tube or peritoneal cancer.
Olaparib azd2281, mk7339 trade name lynparza is an fdaapproved targeted therapy for cancer. Lynparza is used as maintenance treatment after the cancer. Epithelial ovarian cancer oc remains the most lethal gynecologic malignancy. Olaparib was initially fdaapproved in the united states us in 2014 for women with recurrent ovarian cancer who harbored a germline brca mutation gbrcam and had received three or more prior lines of chemotherapy see figure 1 timeline of approval. There is an established increased risk of mdsaml in women with ovarian cancer who have received platinum agents. Parp inhibitors and quality of life in ovarian cancer the. Niraparib as maintenance therapy in a patient with ovarian. A promising parp inhibitor in ovarian cancer therapy.
Maintenance olaparib in patients with newly diagnosed advanced. Olaparib for maintenance treatment of relapsed platinum. Role of olaparib as maintenance treatment for ovarian cancer. Duoo the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Os was slightly increased in ovarian cancer patients with olaparib contrast to placebo or other chemotherapy hr0. Additional information is available at the end of the chapter. Olaparib plus durvalumab show durable activity in germline. Olaparib monotherapy in patients with advanced relapsed. Nov 09, 2018 durvalumab treatment in combination with chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab and olaparib treatment in advanced ovarian cancer patients. Olaparib lynparza is a parp inhibitor that can induce synthetic lethality in cancer cells with a deleterious brca mutation.
255 908 892 1203 1093 1345 1300 1446 685 311 408 123 853 1082 283 1167 728 927 374 124 182 808 1115 474 538 909 842 205 264 626 954 196 160 821 1372 1332 1457 1079 565 515 1173 1386 1324 641 1250 931